Chatting with Proactive's Stephen Gunnion, Kromek Group PLC (AIM:KMK) CEO Arnab Basu shared an optimistic outlook on the company's first-half financial and operational achievements.
With a spotlight on increased revenue, improved gross margins and a notably reduced loss, Basu's insights offer a glimpse into the strategic directions propelling Kromek towards sustained growth.
Stephen Gunnion (SG): Arnab, Kromek's interim results indicate a strong first half with notable financial improvements. Can you elaborate on these achievements?
Arnab Basu (AB): Absolutely, Stephen. We've experienced a period of positive momentum, underpinned by a significant improvement in our EBITDA position and reduced pre-tax losses.
This success stems from our unwavering focus on profitability, achieved through diligent cost control and enhancing our business margins. Our growth has been particularly robust in the advanced imaging and CBRN segments, reflecting our alignment with market demands and our strategic initiatives in these areas.
SG: Could you dive deeper into the growth drivers within your main business segments?
AB: Certainly. Our advanced imaging segment, especially in SPECT and CT modalities, has seen increasing adoption of our CZT material, revolutionizing digital spectrums and enhancing diagnostic capabilities. This trend is underscored by new product launches and significant partnerships, such as our collaboration with a CT Original Equipment Manufacturer (OEM) and Spectrum Dynamics' launch of a new product.
On the CBRN front, global security concerns have spiked demand for our handheld radiation detection tools. Our contract wins and robust pipelines in this segment, alongside partnerships for biosecurity projects with the US and UK governments, mark our strategic advancements and readiness to meet evolving market needs.
SG: With the momentum built in the first half, how do you anticipate this will impact Kromek's performance moving into the full year 2024?
AB: The trajectory we've set in the first half is expected to continue, with the second half traditionally being stronger for us. We're on track to achieve record revenues, a testament to our growth strategy's effectiveness.
Our focus remains on cost control and margin improvement, positioning us to report not only significant revenue growth but also a positive EBITDA for the year. This marks a pivotal step towards our long-term profitability and underscores our commitment to delivering value.